China Unveils Groundbreaking Policy for Innovative Drugs: What the New Commercial Insurance Catalog Means for Investors & FoundersChina Finance Tech in ChinaChina healthcare, commercial insurance, drug policy, Hotgen Biotech, pharmaceutical innovation, RemeGen, Shatshn July 1, 2025
China Unveils a Game-Changing Policy for Innovative Drugs: Here’s What Investors Need to KnowChina Finance Tech in ChinaBiotech, Healthcare, Hotgen Biotech, Pharmaceuticals, policy, RemeGen, Shutaishen, Sino Biopharmaceutical, Yifan Pharmaceutical July 1, 2025
Major Boost for Innovative Drugs Arrives! Adding Fuel to the Hottest Sector in China?China SoftwareAstraZeneca, China Pharma, CSPC Pharmaceutical Group, Healthcare, Investment, RemeGen, Sino Biopharmaceutical June 16, 2025
STAR Market Pharma 2024 Report Card: Profit Growth for 53%, R&D Spend Hits ¥350M AverageChina Finance Tech in ChinaBeiGene, Biopharma, BioRay Pharmaceutical, EndoPuls Therapeutics, Jiangsu Jindiaok Biotechnology, Junshi Biosciences, Kexing Biopharm, Medicilon, MicroPort EP, Nansin Pharm, Notta & Belle, Profitability, R&D, RemeGen, SinoCellTech, STAR Market, Sunny Pharmatech, Sunshine Guojian Pharmaceutical, Tinavi Medical Technologies, United Imaging Healthcare, Xiangyu Medical, Zhixiang Bio May 6, 2025
